Enzon Pharmaceuticals, Inc. financial data

Symbol
ENZN on OTC
Location
20 Commerce Drive, Suite 135, Cranford, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5.07K % -16.7%
Return On Equity -216 % -546%
Return On Assets -5.32 % -265%
Operating Margin -4K % -10.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 74.2M shares 0%
Common Stock, Shares, Outstanding 74.2M shares 0%
Entity Public Float 6.81M USD -10.2%
Common Stock, Value, Issued 742K USD 0%
Weighted Average Number of Shares Outstanding, Basic 74.2M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 74.2M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 26K USD
Operating Income (Loss) -4.16M USD -242%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.12M USD -260%
Income Tax Expense (Benefit) 286K USD -67.3%
Net Income (Loss) Attributable to Parent -2.41M USD -258%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 43.3M USD -7.24%
Other Assets, Current 411K USD +22%
Assets, Current 43.7M USD -7.03%
Deferred Income Tax Assets, Net 26K USD -91.5%
Assets 43.7M USD -7.58%
Accounts Payable, Current 331K USD 0%
Accrued Liabilities, Current 209K USD +95.3%
Liabilities, Current 540K USD +23.3%
Retained Earnings (Accumulated Deficit) -72.2M USD -3.45%
Stockholders' Equity Attributable to Parent -923K USD -133%
Liabilities and Equity 43.7M USD -7.58%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -618K USD -346%
Net Cash Provided by (Used in) Financing Activities -1.28M USD 0%
Common Stock, Shares Authorized 170M shares 0%
Common Stock, Shares, Issued 74.2M shares 0%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.89M USD -84.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 43.3M USD -7.24%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 32.4M USD -4.89%
Deferred Tax Assets, Gross 32.4M USD -5.84%
Deferred Income Tax Expense (Benefit) 364K USD -68%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2.96M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 2K USD 0%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%